Disclosure of Major Holdings under Law 163/2024
Company Release
Nanoform Finland Plc
May 29, 2024
12.30 Finnish time / 11.30 Swedish time
Disclosure of Major Holdings under Law 163/2024
Nanoform Finland Plc ("Nanoform" or the "Company") has on May 28, 2024, received a notification from Edward Hæggström (CEO of Nanoform Finland Plc). The notification was made pursuant to law 163/2024 amending the Finnish Securities Market Act (the “Act”). Under the transition rules of the Act, a shareholder in a First North listed company is in required to notify major holdings within two months from the entry into force of the Act. The notification has been made on the basis of the transition rules of the Act, and not an acquisition or disposal of shares.
Nanoform has one series of shares in which each share carries one vote. The percentage numbers indicate the shareholding on the date the Act entered into force on April 19, 2024. The aggregate number of shares at the entry into force of the Act was 78,445,164.
| Total positions of Edward Hæggström subject to the notification obligation: | ||||
| % of shares and voting rights (total of 7.A) |
% of shares and voting rights through financial instruments (total of 7.B) |
Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issue (on April 19, 2024) | |
| Resulting situation on the date on which threshold was crossed or reached | 6,90% | 0,08% | 6,98% | 78,445,164 |
| Position of previous notification (if applicable) | - | - | - | |
| Notified details of the resulting situation on the date on which the threshold was crossed or reached: | ||||
| A: Shares and voting rights | ||||
| Class/type of sharesISIN code (if possible) |
Number of shares and voting rights | % of shares and voting rights | ||
| Direct(SMA 9:5) | Indirect(SMA 9:6 and 9:7) | Direct(SMA 9:5) | Indirect(SMA 9:6 and 9:7) | |
| FI4000330972 | 5,409,405 | - | 6,90% | - |
| - | - | - | - | - |
| - | - | - | - | - |
| SUBTOTAL A | 5,409,405 | 6,90% | ||
| B: Financial Instruments according to SMA 9:6a | |||||
| Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| Stock option | 1.1.2029 | Until 1.1.2029 | Physical settlement | 59,774 | 0,08 |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| SUBTOTAL B | 59,774 | 0,08 | |||
| Information in relation to the person subject to the notification obligation ☒ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.☐ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: |
|||
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
The notification of major shareholdings is based on the law 163/2024, in accordance with which a shareholder of a First North company is required to notify certain major shareholdings within two months from the entry into force of the law, in the event that the holding of shares or votes on the entry into force of the law on April 19, 2024 was at least 5 % and it had not been made public prior. The numbers and percentages in the notification are current as of the date of the entry into force of the law 163/2024 which was April 19,2024.
Nanoform Finland Plc
For further information, please contact:
Peter Hänninen, General Counsel
peter.hanninen@nanoform.com, +358 50 353 0408
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com, +46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Carnegie Investment Bank AB (publ), +46 8-588 68 570. For more information, please visit www.nanoform.com.